Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of tissue repair products specialist Anika Therapeutics, Inc. (NASDAQ:ANIK) soared 26% today after its quarterly results and outlook impressed Wall Street.
So what: The stock has soared over the past two years on a string of better-than-expected growth, and today's wide Q2 beat -- EPS of $0.40 versus the consensus of $0.23 -- coupled with a positive outlook only reinforces that momentum. In fact, revenue increased a solid 6% while gross margins expanded to 68.5%, from 57.2%, suggesting that its competitive position and operating efficiency are improving rapidly.
Now what: Management expected continued growth and profitability improvement for the rest of 2013.
"Our viscosupplementation business is strong, and we are driving efficiencies in our operations and manufacturing," said President and CEO Charles H. Sherwood. "We are also enthusiastic about our product pipeline."
Of course, with the stock now up a whopping 180% over its 52-week lows and trading at a 20-plus forward P/E, much of that enthusiasm might already be baked into the valuation.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Biotech Stocks to Buy in May
On the hunt for a biotech bargain? Our contributors think you should give these stocks a closer look.
3 Biotech Stocks to Buy in December
Three Motley Fool analysts tell investors which biotechnology stocks are on their wish list this month.
Anika Therapeutics, Inc Surges On Approval, but Is It Overpriced Now?
Anika (ANIK) won FDA approval for Monovisc, but sales will have to be strong to justify its recent move higher.